Research to be Conducted at McGill University to Study CELEXT07 and the Role of
Functional Microbiome in Cannabis Breeding Strategies Against
Biotic Stress
MONTREAL, Nov. 18, 2019 /CNW/ – Mondias Natural Products
Inc. (TSXV: NHP) specializing in evidence-based
botanical products for the healthcare and bio-agriculture markets
today announces the approval of a two-year Mitacs funding to
develop a next-generation CELEXT07 plant biostimulant based on
microbial consortia. According to agriculture industry market
report, the biopesticide market is expected to exceed US
$3B in 2019; and to reach US
$6B by 2023. Established global
players are actively seeking Natural Organic alternative products
to enhance crop yield and to protect the food chain.
The funding is awarded to Professor Suha Jabaji at the
Department of Plant Science, Faculty of Agricultural and
Environmental Sciences McGill
University. Mondias contribution of $80,000 will be matched by $60,000 from the Mitacs Elevate program,
resulting in total research investment of $140,000.
Dr. Jamil Samsatly, Mondias CSO stated that "with this funding
we continue to expand our research and development efforts for
CELEXT07, a commercial stage product, in continued collaboration
with McGill University. Mondias
is developing a pipeline of targeted bio-agriculture derivatives
based on CELEXT07 and having crop specificity. In this
research program we are studying cannabis plant microbiome in order
to improve safety, quality and yield of dried flower by treating
fungal diseases from seed to soil."
Dr. Samsatly mentioned that "we are delighted to be awarded the
Mitacs funding to further develop CELEXT07 with Dr. Jabaji and her
research team at McGill. CELEXT07 was previously developed in
collaboration with the same laboratory and in 2016 Mondias received
a Canadian Food Inspection Agency (CFIA) approval as a specialty
fertilizer for use in greenhouses, nurseries and golf
courses." Dr. Samsatly also added that "CELEXT07 is our most
advanced agriculture product and data demonstrated that it is a
biostimulant and biocontrol agent that will be an important natural
based crop management product once broader approvals are submitted
and received internationally."
The Elevate Fellowship funding will commence upon confirmation
of initial payment by Mondias prior to the fellowship
start date and the appointment of a PhD lead investigator having
Postdoctoral status at McGill University.
CELEXT07 is patent pending on herbal phytosanitary composition
and methods for the prevention and treatment of plant infections in
Australia, Brazil, Canada, China, European Union, and the US and the
World Intellectual Property Organization (WIPO). Mondias has
invested in research programs in collaboration with McGill's
Faculty of Agricultural and Environmental Sciences to develop
CELEXT07.
About Mondias Natural Products Inc.
Mondias
specializes in the commercialization and development of
evidence-based botanical products for the healthcare,
bio-agriculture and organic markets. The company sells both oral
and topical botanical agents to help manage unmet medical needs
through its Holizen Laboratories division. Mondias is also
developing botanical-based specialty fertilizers for use on
household plants, lawns and golf courses and in urban gardens,
nurseries and greenhouses, in collaboration with McGill's Faculty
of Agricultural and Environmental Sciences.
For more information, visit: www.mondias.ca
About Mitacs
Mitacs is a not-for-profit organization
that fosters growth and innovation in Canada by solving business challenges with
research solutions from the best academic institutions at home and
around the world. Working with more than 70 universities,
Mitacs builds partnerships that support industrial and social
innovation in Canada. Open to all
disciplines and all industry sectors, projects can span a wide
range of areas, including manufacturing, business processes, IT,
social sciences, design and more. Mitacs is funded by the
Government of Canada, the
Government of Ontario, and every
other province, as well as academic and industry partners.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this
release may contain forward-looking information. All statements,
other than statements of historical fact, that address activities,
events or developments that the Company believes, expects or
anticipates will or may occur in the future (including, without
limitation, statements regarding potential acquisitions and
financings) are forward-looking statements. Forward-looking
statements are generally identifiable by the use of the words
"may", "will", "should", "continue", "expect", "anticipate",
"estimate", "believe", "intend", "plan" or "project" or the
negative of these words or other variations on these words or
comparable terminology. Forward-looking statements are subject to a
number of risks and uncertainties, many of which are beyond the
Company's ability to control or predict, that may cause the actual
results of the Company to differ materially from those discussed in
the forward-looking statements. Factors that could cause actual
results or events to differ materially from current expectations
include the Company's inability to obtain sufficient financing to
execute its business plan; competition; regulation; anticipated and
unanticipated costs and delays; the success of the Company's
research and development strategies; the ability to obtain orphan
drug status; the applicability of the discoveries made; the
successful and timely completion and uncertainties related to the
regulatory approval process; the timing of clinical trials; the
timing and outcomes of regulatory or intellectual property
decisions; and other risks disclosed in the Company's public
disclosure record on file with the relevant securities regulatory
authorities. Although the Company has attempted to identify
important factors that could cause actual results or events to
differ materially from those described in forward-looking
statements, there may be other factors that cause results or events
not to be as anticipated, estimated or intended. Readers should not
place undue reliance on forward-looking statements. The
forward-looking statements in this news release are made as of the
date of this news release, and the Company does not undertake any
obligation to publicly update them to reflect new information or
subsequent events or otherwise except as required by applicable
securities legislation.
SOURCE Mondias Natural Products Inc.